Zacks Research Weighs in on GSK’s FY2024 Earnings (NYSE:GSK)

GSK plc (NYSE:GSK) – Stock analysts at Zacks Research upped their FY2024 earnings per share (EPS) estimates for shares of GSK in a research report issued to clients and investors on Tuesday, November 19th. Zacks Research analyst E. Bagri now forecasts that the pharmaceutical company will post earnings per share of $4.12 for the year, up from their prior estimate of $4.11. The consensus estimate for GSK’s current full-year earnings is $4.06 per share. Zacks Research also issued estimates for GSK’s Q1 2026 earnings at $1.14 EPS and Q3 2026 earnings at $1.57 EPS.

A number of other research analysts also recently weighed in on the stock. Argus upgraded shares of GSK to a “strong-buy” rating in a report on Wednesday, August 7th. Guggenheim downgraded shares of GSK from a “buy” rating to a “neutral” rating in a research report on Thursday, October 31st. Jefferies Financial Group cut GSK from a “buy” rating to a “hold” rating and reduced their price target for the stock from $53.00 to $39.50 in a research report on Tuesday, November 12th. Barclays upgraded GSK to a “hold” rating in a research note on Tuesday, August 27th. Finally, Deutsche Bank Aktiengesellschaft downgraded GSK from a “buy” rating to a “hold” rating in a research note on Friday, November 15th. Seven equities research analysts have rated the stock with a hold rating and three have issued a strong buy rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $43.25.

GSK Stock Performance

Shares of NYSE GSK opened at $33.96 on Friday. The company has a debt-to-equity ratio of 0.98, a current ratio of 0.81 and a quick ratio of 0.53. GSK has a one year low of $32.83 and a one year high of $45.92. The business’s 50-day moving average price is $38.09 and its two-hundred day moving average price is $40.35. The company has a market capitalization of $70.38 billion, a P/E ratio of 22.05, a price-to-earnings-growth ratio of 1.29 and a beta of 0.66.

Institutional Investors Weigh In On GSK

A number of institutional investors and hedge funds have recently made changes to their positions in GSK. Stock Yards Bank & Trust Co. bought a new stake in GSK in the third quarter valued at about $210,000. Second Line Capital LLC bought a new position in GSK during the 3rd quarter worth approximately $245,000. Rehmann Capital Advisory Group raised its stake in GSK by 6.3% during the 3rd quarter. Rehmann Capital Advisory Group now owns 5,608 shares of the pharmaceutical company’s stock worth $232,000 after buying an additional 332 shares during the period. TD Private Client Wealth LLC lifted its holdings in GSK by 36.9% during the third quarter. TD Private Client Wealth LLC now owns 12,422 shares of the pharmaceutical company’s stock worth $508,000 after acquiring an additional 3,346 shares in the last quarter. Finally, Sunbelt Securities Inc. raised its holdings in GSK by 73.8% during the 3rd quarter. Sunbelt Securities Inc. now owns 711 shares of the pharmaceutical company’s stock worth $29,000 after buying an additional 302 shares during the period. Institutional investors own 15.74% of the company’s stock.

Insider Buying and Selling

In other GSK news, major shareholder Plc Gsk purchased 2,791,930 shares of the business’s stock in a transaction that occurred on Friday, September 27th. The stock was acquired at an average cost of $8.00 per share, with a total value of $22,335,440.00. Following the completion of the acquisition, the insider now directly owns 16,775,691 shares of the company’s stock, valued at $134,205,528. This represents a 19.97 % increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. 10.00% of the stock is currently owned by corporate insiders.

GSK Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, January 9th. Shareholders of record on Friday, November 15th will be issued a dividend of $0.3928 per share. The ex-dividend date of this dividend is Friday, November 15th. This is a boost from GSK’s previous quarterly dividend of $0.38. This represents a $1.57 dividend on an annualized basis and a dividend yield of 4.63%. GSK’s dividend payout ratio (DPR) is presently 99.35%.

About GSK

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.